Primary information |
---|
ID | antitb_1388, |
Name | 21482189 |
N-Terminal modification | Hepcidin |
C-Terminal Modification | DTHFPICIFCCGCCHRSKCGMCCKT |
Chemical Modification | Free |
Linear/Cyclic | Free |
Length | Disulphide linkage between cys7-23, cys10-13, cys11-19,cys14-22 |
Chirality | Cyclic |
Nature | 25 |
Source | L |
Origin | Cationic |
Species | Natural |
Strain | Human alveolar type 2 epithilium |
Inhibition Concentration | Mycobacterium tuberculosis |
In Vitro/ In vivo | Mycobacterium H37Rv |
Inhibition Concentration | in vivo |
Sequence | 2011 |
Cytotoxicity | A549 cell line |
In vivo Model | NA |
Lethal Dose | No cytotoxicity |
Immune Responce | BALB/C |
Mechanism of Action | NA |
Target | Increased production of TNF-α, IL-1α |
Combination Therapy | NA |
Other activities | Mycobacterium tuberculosis + IFN-Î¥ |
PMID | |
Year of Publication | antimicrobial |
Tertiary Structure (Technique) | Not Predicted), |
Primary information |
---|
ID | antitb_1544, |
Name | 25613372 |
N-Terminal modification | Hepcidin |
C-Terminal Modification | DTHFPICIFCCGCCHRSKCGMCCKT |
Chemical Modification | Free |
Linear/Cyclic | Free |
Length | None |
Chirality | Linear |
Nature | 25 |
Source | L |
Origin | Cationic |
Species | Protein derived |
Strain | Derived from Hepcidin protein |
Inhibition Concentration | Mycobacterium tuberculosis |
In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv |
Inhibition Concentration | in vitro |
Sequence | 2015 |
Cytotoxicity | NA |
In vivo Model | NA |
Lethal Dose | NA |
Immune Responce | NA |
Mechanism of Action | NA |
Target | induce expression of IFN-γ |
Combination Therapy | Cause structural damage to mycobacteria |
Other activities | NA |
PMID | NA |
Year of Publication | NA |
Tertiary Structure (Technique) | Not Predicted), |